Lantern Pharma is trading 6.3% lower at $0.63 on October 16, 2026, with no clear company-specific catalyst identified.
- Major U.S. indexes are lower, and biotech-sector pressure is also reported; these factors may be contributing, but the evidence does not establish a specific cause.
- The October 15 ThinkEquity presentation is prior-day context, not an identified catalyst for this move.
- The supplied price context is the basis for the current price and percentage.